Melanoma Molecular Maps Projects


Targeted Therapy Database

A systematic collection of the scientific knowledge regarding the development of targeted therapy for melanoma. Since data are gathered in a computationally compatible fashion, the database can be utilized for the identification of prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based on the patient's molecular profile (drug ranking system). In particular the TTD can be queried for the following purposes:

  1. To provide both basic researchers and clinical investigators with an unprecedented synopsis of the available scientific literature on the development of targeted therapy for melanoma;

  2. To obtain summaries of the current evidence on the relationship between each single molecule (or set of molecules) and the efficacy (toxicity) of a given therapeutic agent (or set of therapeutic agents);

  3. To match the patient/cancer molecular profile with the available scientific evidence on the targeted therapy of melanoma, thus developing a drug ranking system for the personalized treatment of melanoma.

Please click on the following links to open the TARGETED THERAPY DATABASE (TTD) and its User's Guide.

The second version of the Targeted Therapy Database (TTD) is now available, with more records on the personalized treatment of melanoma.


"Targeted Therapy Database (TTD): A Model To Match Patient's Molecular Profile With Current Knowledge On Cancer Biology". By: Mocellin S., Shrager J., Scolyer R., Pasquali S., Verdi D., Marincola F.M., Briarava M., Gobbel R., Rossi C., Nitti D.
PLoS One (2010), 5(8):e11965

Search the site

Risk Assessment Tools

TNM Staging System | Total Dermoscopy Score | Thin Melanoma Prognosis |

Melanoma News

Biochip-Based Genotyping Assay for Detection of Polymorphisms in Pigmentation Genes Associated with Cutaneous Melanoma.
Fesenko DO, Chudinov AV, Surzhikov SA, Zasedatelev AS
Genet Test Mol Biomarkers. 2016 Feb 5;():.
PMID: 26848990 [PubMed - as supplied by publisher]

Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
Imrédi E, Tóth B, Doma V, Barbai T, Rásó E, Kenessey I, Tímár J
Melanoma Res. 2016 Feb 4;():.
PMID: 26848795 [PubMed - as supplied by publisher]

Characteristics and Treatment of Cutaneous Melanoma of the Foot.
Nam KW, Bae YC, Nam SB, Kim JH, Kim HS, Choi YJ
Arch Plast Surg. 2016 Jan;43(1):59-65.
PMID: 26848447 [PubMed]

Sentinel Lymph Nodes in Cutaneous Melanoma.
Prieto VG
Surg Pathol Clin. 2009 Sep;2(3):553-63.
PMID: 26838540 [PubMed]

Cutaneous melanoma frequencies and seasonal trend in 20 years of observation of a population characterised by excessive sun exposure.
Bonin S, Albano A, di Meo N, Gatti A, Stinco G, Zanconati F, Trevisan G
Radiol Oncol. 2015 Dec;49(4):379-85.
PMID: 26834525 [PubMed]

NCBI's Disclaimer and Copyright notice